Page 45 - Manual of Equine Field Surgery

Field Anesthesia 41
10. Ballard S, Shults T, Kownacki AA, et al: The phar-
macokinetics, pharmacological responses and
behavioral effects of acepromazine in the horse,
J Vet Pharmacol Ther 5:21, 1982.
11. Principles of sedation, analgesia and premedica-
tion. In Hall LW, Clarke KW, Trim CM, editors:
Veterinary anaesthesia, ed 10, St Louis, 2001, WB
Saunders.
12. Gillespie JR, Schalm CW, Tyler WS: Hematologic
response of the horse to general anesthesia: a
review and new data. Proceedings of the First
International Symposium on Equine Hematology
Michigan State University, East Lansing, Mich.,
490, 1975.
13. Bloor BC, Schmeling WT: Cardiovascular effects of
alpha2-adrenoreceptors, Anaestn Pharmacol Rev
1:246, 1993.
14. Sarazan RD, Starke WA, Krause GF, et al: Cardio-
vascular effects of detomidine, a new alpha 2-
adrenoceptor agonist, in the conscious pony, J Vet
Pharmacol Ther 12:378, 1989.
15. Yamashita K, Tsubakishita S, Futaok S, et al: Car-
diovascular effects of medetomidine, detomidine
and xylazine in horses, J Vet Med Sci 62:1025, 2000.
16. Wagner AE, Muir WW III, Hinchcliff KW: Cardio-
vascular effects of xylazine and detomidine in
horses, Am J Vet Res 52:651, 1991.
17. Nunez E, Steffey EP, Ocampo L, et al: Effects of
alpha2-adrenergic receptor agonists on urine pro-
duction in horses deprived of food and water, Am
J Vet Res 65:1342, 2004.
18. Thurmon JC, Steffey EP, Zinkl JG, et al: Xylazine
causes transient dose-related hyperglycemia and
increased urine volumes in mares, Am J Vet Res
45:224, 1984.
19. Schatzmann U, Jossfck H, Stauffer JL, et al: Effects
of alpha 2-agonists on intrauterine pressure and
sedation in horses: comparison between detomi-
dine, romifidine and xylazine. Zentralbl Veterin-
armed A 41:523, 1994.
20. Spyridaki MH, Lyris E, Georgoulakis I, et al: Deter-
mination of xylazine and its metabolites by GC-MS
in equine urine for doping analysis, J Pharm
Biomed Anal 35:107, 2004.
21. Salonen JS, Suolinna EM: Metabolism of detomi-
dine in the rat. I. Comparison of 3H-labelled
metabolites formed in vitro and in vivo, Eur J Drug
Metab Pharmacokinet 13:53, 1988.
22. Salonen JS, Vaha-Vahe T, Vainio 0, et al: Single-
dose pharmacokinetics of detomidine in the horse
and cow, J Vet Pharmacol Ther 12:65, 1989.
23. Mutlib AE, Chui YC, Young LM, et al: Characteri-
zation of metabolites of xylazine produced in vivo
and iI1 vitro by LC/MS/MS and by GC/MS, Drug
Metab Dispos 20:840, 1992.
24. Preeman SL, Bowen IM, Bettschart-Wolfensberger
R, et al: Cardiovascular effects of romifidine in the
standing horse, Res Vet Sci 72:123, 2002.
25. England GC, Clarke KW, Goossens L: A comparison
of the sedative effects of three alpha 2-adrenoceptor
agonists (romifidine, detomidine and xylazine) in
the horse, J Vet Pharmacol Ther 15:194, 1992.
26. Hamm D, Turchi P, Jochle W: Sedative and an-
algesic effects of detomidine and romifidine in
horses, Vet Rec 136:324, 1995.
27. Hobo S, Aida H, Yoshida K: Assessment of the seda-
tive effect of medetomidine and determination of
its optimal dose in thoroughbred horses, J Vet Med
Sci 57:507, 1995.
28. Tranquilli WJ, Maze M: Clinical pharmacology and
use of alpha2-adrenergic agonists in veterinary
anaesthesia, Anaesth Pharmacol Rev 1:297, 1993.
29. Buchner HH, Kubber P, Zohmann E, et al: Sedation
and antisedation as tools in equine lameness exam-
ination, Equine Vet J Suppl 30:227, 1999.
30. Kollias-Baker CA, Court MH, Williams LL: Influ-
ence of yohimbine and tolazoline on the cardiovas-
cular, respiratory, and sedative effects of xylazine in
the horse, J Vet Pharmacol Ther 16:350, 1993.
31. Cornick-Seahorn JL, Seahorn TL: Cardiopul-
monary and behavioral effects of midazolam HCl
and reversal with flumazenil in pony foals,
Proceedings of the 22nd Annual Meeting of the
American College of Veterinary Anesthesiologists,
Phoenix, Ariz., 17, 2004.
32. Stoelting RK: Benzodiazepines. In Stoelting RK,
editor: Pharmacology and physiology in anesthetic
practice, ed 3, Philadelphia, 1999, Lippincott Raven,
33. Marland A, Sarkar P, Leavitt R: The urinary elimi-
nation profiles of diazepam and its metabolites,
nordiazepam, temazepam, and oxazepam, in the
equine after a 10-mg intramuscular dose, J Anal
Toxicol 23:29, 1999.
34. Wall R, Muir WW III: Hemolytic potential of
guaifenesin i11 cattle. Cornell Vet 80:209, 1990.
35. Grandy JL, McDonell WN: Evaluation of concen-
trated solutions of guaifenesin for equine anesthe-
sia, J Am Vet Med Assoc 176:619, 1980.
36. Herschl MA, Trim CM, Mahaffey EA: Effects of 50/o
and 10% guaifenesin infusion on equine vascular
endothelium, Vet Surg 21:494, 1992.
37. Davis LE, Wolff WA: Pharmacokinetics and metab-
olism of glyceryl guaiacolate in ponies, Am J Vet Res
31:469, 1970.
38. Muir WW, Skarda RT, Sheehan WC: Cardiopul-
monary effects of narcotic agonists and a partial
agonist in horses, A·m J Vet Res 39:1632, 1978.
39. Amadon RS, Craig AH: The actions of morphine
011 the horse. Preliminary studies: diacetylmor-
phine (heroin), dihydrodesoxymorphine-D (deso-
morphine) and dihydroterocodine, J Am Vet Med
Assoc 91:674, 1937.
-----: 40. Mircica E, Clutton RE, Kyles KW, et al: Problems
associated with perioperative morphine in horses:
a retrospective case analysis, Vet Anaesth A11.alg
30:147, 2003.